Table 2 Outcomes of the study population

From: A randomized trial testing digital medicine support models for mild-to-moderate alcohol use disorder

Characteristic

Self-monitored

Peer-supported

Clinically integrated

Total

 

n

(M, SD)

n

(M, SD)

n

(M, SD)

n

(M, SD)

Percentage of heavy drinking days, PHDD

 Baseline

185

(37.1, 30.6)

186

(36.2, 31.2)

186

(41.9, 31.4)

557

(38.4, 31.1)

 3 Months

178

(25.5, 28.2)

178

(23.8, 30.1)

162

(29.4, 28.2)

518

(26.1, 28.9)

 6 Months

161

(23.6, 27.3)

162

(24.3, 30.1)

139

(25.3, 31.2)

462

(24.4, 29.4)

 9 Months

145

(20.3, 24.6)

145

(21.2, 27.7)

109

(22.4, 27.4)

399

(21.2, 26.5)

 12 Months

139

(24.4, 28.2)

130

(21.4, 28.9)

100

(21.3, 30.4)

369

(22.5, 29)

 ARR or RRR*

−12.7 or −34.2%

−14.8 or −40.9%

−20.6 or −49.2%

−15.9 or 41.4%

Quality of life-physical health, QOL-PH*

 Baseline

185

(48.4, 6.3)

186

(48.1, 6.7)

186

(48.3, 6.5)

557

(48.3, 6.5)

 3 months

178

(48.6, 6.6)

177

(48.4, 6.6)

162

(47.8, 6.7)

517

(48.3, 6.6)

 6 months

161

(48.6, 6.4)

162

(48.7, 7.2)

139

(48.1, 7.2)

462

(48.5, 6.9)

 9 months

145

(48.5, 6.3)

145

(49.6, 6.1)

109

(48.1, 7.4)

399

(48.8, 6.6)

 12 months

139

(48.6, 6.8)

130

(49.3, 6.4)

100

(48.1, 7.5)

369

(48.6, 6.9)

 ARR or RRR*

−0.2 or −0.4%

1.2 or 2.5%

−0.2 or −0.4%

0.3 or 0.6%

Quality of life-mental health, QOL-MH*

 Baseline

185

(45.5, 6.9)

186

(45,5, 7.5)

186

(45.4, 6.9)

557

(45.4, 7.1)

 3 Months

178

(46.3, 7)

177

(45,9, 7.3)

162

(47.3, 7.1)

517

(46.5, 7.1)

 6 Months

161

(46.4, 7.1)

162

(47.4, 7.5)

139

(48, 7.5)

462

(47.2, 7.4)

 9 Months

145

(46.4, 7.2)

145

(47.3, 7.2)

109

(48.1, 7.2)

399

(47.2, 7.2)

 12 Months

139

(46.7, 8.3)

130

(47.7, 8.3)

100

(48.1, 7)

369

(47.4, 8)

 ARR or RRR**

1.2 or 2.6%

2.2 or 4.8%

2.7 or 5.9%

1.8 or 4%

  1. M mean, SD standard deviation, n sample size, ARR absolute risk reduction, RRR relative risk reduction.
  2. *QOL measures are T-scores.
  3. **ARR and RRR were calculated between values in baseline and 12 months.